Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized furosemide versus placebo or no nebulization for acute dyspnea in EMS transport
IRCT20171014036753N2Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of furosemide in Dyspnoea (SOB) (3 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: pulse rate, respiratory rate and 3 more. Started Nov 2018; status: completed.
02
Drugs
furosemide
03
Conditions
Dyspnoea (SOB)
Beyond the preview
Go deeper on IRCT20171014036753N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171014036753N2.